Literature DB >> 31444607

Morphomolecular analysis of the immune tumor microenvironment in human head and neck cancer.

Mohamed Badr1, Korinna Jöhrens1,2, Michael Allgäuer3, Melanie Boxberg4, Wilko Weichert4,5,6,7, Ingeborg Tinhofer8, Carsten Denkert1,9,5,6,7, Peter Schirmacher3,5,6,7, Albrecht Stenzinger3,5,6,7, Jan Budczies10,11,12,13,14.   

Abstract

Immunotherapy is effective in head and neck squamous cell carcinoma (HNSCC), but only a minority of patients responds to immune checkpoint blockade (ICB). To contribute to a better understanding of the underlying immune biology, we combined histomorphological evaluation and molecular analysis of the HNSCC immune microenvironment in the TCGA cohort. Analyzing digital HE-stained slides, a method for classification of tumor infiltrating lymphocytes (TILs) in the intra-epithelial compartment (ieTILs, present vs. absent) and the stromal compartment (strTILs, high vs. low) was established. We also analyzed the abundance of eight immune cell populations (estimated from RNAseq data) and PD-L1 mRNA expression. Status of ieTILs and status of strTILs were concordant for 61%, but discordant for 39% of tumors. In univariate survival analysis, ieTILs were a positive prognostic marker for DFS in the study cohort (HR = 0.66, p = 0.015) and in the HPV- subcohort (HR = 0.68, p = 0.04), but not in the HPV + subcohort. T cells were a positive prognostic marker for DFS in the study cohort (HR = 0.80, p = 0.03) and in the HPV + subcohort (HR = 0.20, p = 0.001), but not in the HPV- subcohort. In univariate survival analysis, PD-L1 mRNA expression was neither associated with DFS nor with OS. However, in bivariate and multivariate analyses including both PD-L1 mRNA levels and T cells, PD-L1 was a negative prognostic marker of DFS and OS, while T cells remained a positive prognostic marker. In conclusion, ieTILs and strTILs were non-redundant biomarkers in HNSCC and should be evaluated separately. The identified prognostic markers should be evaluated for predictivity in ICB-treated patients.

Entities:  

Keywords:  Head and neck squamous cell cancer (HNSCC); Immune checkpoint blockade; PD-L1; T cells; Tumor infiltrating lymphocytes (TILs)

Mesh:

Substances:

Year:  2019        PMID: 31444607     DOI: 10.1007/s00262-019-02378-w

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  5 in total

Review 1.  Understanding the tumor microenvironment in head and neck squamous cell carcinoma.

Authors:  Habib Sadeghi Rad; Yavar Shiravand; Payar Radfar; Rahul Ladwa; Chris Perry; Xiaoyuan Han; Majid Ebrahimi Warkiani; Mark N Adams; Brett Gm Hughes; Ken O'Byrne; Arutha Kulasinghe
Journal:  Clin Transl Immunology       Date:  2022-06-06

2.  The Double-Edge Role of the Addition of Adjuvant Chemotherapy to Concurrent Chemoradiotherapy in the Treatment of Nasopharyngeal Carcinoma.

Authors:  Zhong-Guo Liang; Fan Zhang; Bin-Bin Yu; Ling Li; Song Qu; Ye Li; Ying Guan; Ren-Ba Liang; Lu Han; Xiao-Dong Zhu
Journal:  Cancer Manag Res       Date:  2020-02-04       Impact factor: 3.989

3.  Integrated Analysis Reveals ENDOU as a Biomarker in Head and Neck Squamous Cell Carcinoma Progression.

Authors:  Chengzhi Xu; Yunbin Zhang; Yupeng Shen; Yong Shi; Ming Zhang; Liang Zhou
Journal:  Front Oncol       Date:  2021-02-05       Impact factor: 6.244

Review 4.  Tumor-Infiltrating Lymphocytes in Head and Neck Cancer: Ready for Prime Time?

Authors:  Alhadi Almangush; Stijn De Keukeleire; Sylvie Rottey; Liesbeth Ferdinande; Tijl Vermassen; Ilmo Leivo; Antti A Mäkitie
Journal:  Cancers (Basel)       Date:  2022-03-18       Impact factor: 6.639

5.  Establishment and characterization of patient-derived head and neck cancer models from surgical specimens and endoscopic biopsies.

Authors:  Daniel Strüder; Theresa Momper; Nina Irmscher; Mareike Krause; Jan Liese; Sebastian Schraven; Annette Zimpfer; Sarah Zonnur; Ann-Sophie Burmeister; Björn Schneider; Bernhard Frerich; Robert Mlynski; Christina Große-Thie; Christian Junghanss; Claudia Maletzki
Journal:  J Exp Clin Cancer Res       Date:  2021-08-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.